118 related articles for article (PubMed ID: 7447951)
1. Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
Hagan RM; Raxworthy MJ; Gulliver PA
Biochem Pharmacol; 1980 Dec; 29(23):3123-6. PubMed ID: 7447951
[No Abstract] [Full Text] [Related]
2. The effect of bulk hydrogen ion concentration upon the apparent kinetic parameters of purified pig liver catechol O-methyltransferase.
Raxworthy MJ; Gulliver PA
Biochim Biophys Acta; 1986 Apr; 870(3):417-25. PubMed ID: 3754465
[TBL] [Abstract][Full Text] [Related]
3. Kinetic characterization of the oxidation of carbidopa and benserazide by tyrosinase and peroxidase.
Munoz-Munoz JL; Garcia-Molina F; Garcia-Molina M; Tudela J; García-Cánovas F; Rodriguez-Lopez JN
Biosci Biotechnol Biochem; 2009 Jun; 73(6):1308-13. PubMed ID: 19502746
[TBL] [Abstract][Full Text] [Related]
4. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
Drugs; 1976; 11(5):329-77. PubMed ID: 782834
[No Abstract] [Full Text] [Related]
5. Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors.
Clark WG; Oldendorf WH; Dewherst WG
J Pharm Pharmacol; 1973 May; 25(5):416-8. PubMed ID: 4146401
[No Abstract] [Full Text] [Related]
6. The inhibition of catechol-O-methyltransferase by 2,3-dihydroxypyridine.
Raxworthy MJ; Youde IR; Gulliver PA
Biochem Pharmacol; 1983 Apr; 32(8):1361-4. PubMed ID: 6860355
[TBL] [Abstract][Full Text] [Related]
7. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
8. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines.
Gordonsmith RH; Raxworthy MJ; Gulliver PA
Biochem Pharmacol; 1982 Feb; 31(3):433-7. PubMed ID: 6803810
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
[No Abstract] [Full Text] [Related]
10. Catechol O-methyltransferase.
Borchardt RT
Methods Enzymol; 1981; 77():267-72. PubMed ID: 7329304
[No Abstract] [Full Text] [Related]
11. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Jorga KM; Nicholl DJ
Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
[TBL] [Abstract][Full Text] [Related]
12. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Rondot P
Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
[No Abstract] [Full Text] [Related]
13. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Müller T
Int Rev Neurobiol; 2010; 95():49-71. PubMed ID: 21095459
[TBL] [Abstract][Full Text] [Related]
14. 1-methyl-4-phenylpyridinium and catechol-O-methyltransferase.
Byrne JM; Tipton KF
Biochem Soc Trans; 1995 May; 23(2):350S. PubMed ID: 7672380
[No Abstract] [Full Text] [Related]
15. Photoaffinity labeling of catechol O-methyltransferase with 8-azido-S-adenosylmethionine.
Kaiser II; Kladianos DM; Van Kirk EA; Haley BE
J Biol Chem; 1983 Feb; 258(3):1747-51. PubMed ID: 6337144
[TBL] [Abstract][Full Text] [Related]
16. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and inhibition studies on catechol-O-methyltransferase affinity labelling by N-(3,4-dihydroxyphenyl)maleimide.
Piedrafita FJ; Fernandez-Alvarez E; Nieto O; Tipton KF
Biochem J; 1992 Sep; 286 ( Pt 3)(Pt 3):951-8. PubMed ID: 1417755
[TBL] [Abstract][Full Text] [Related]
18. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
[TBL] [Abstract][Full Text] [Related]
19. 5,6-Dihydroxytryptamine is a substrate for catechol O-methyltransferase.
Fuller RW; Roush BW
Biochem Pharmacol; 1974 Aug; 23(15):2208-9. PubMed ID: 4416934
[No Abstract] [Full Text] [Related]
20. L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Dousa MK; Weinshilboum RM; Muenter MD; Offord KP; Decker PA; Tyce GM
J Neural Transm (Vienna); 2003 Aug; 110(8):899-910. PubMed ID: 12898345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
